Clinical Trials Logo

Clinical Trial Summary

This study was designed to assess the efficacy of adding pentoxifylline to losartan in comparison with increasing dose of losartan in type 2 diabetes patients with nephropathy. also the effect of pentoxifylline on N terminal brain natriuretic peptide (NT-pro BNP) and C-reactive protein

Clinical Trial Description

Addition of pentoxifylline to losartan provides antiproteinuric effects in type 2 diabetes patients with nephropathy that might relate to its effect on N terminal brain natriuretic peptide (NT-pro BNP) and C-reactive protein.

Pentoxifylline is a phosphodiestrase inhibitor with anti-inflammatory effects that was used in type 2 diabetes patients with nephropathy for treatment of diabetes complications.

NT-Pro BNP, which is released from the heart due to wall stress and pressures, is known as a diagnostic and prognostic marker for heart failure and cardiovascular mortality in type 2 diabetes. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

NCT number NCT03006952
Study type Interventional
Source Tehran University of Medical Sciences
Status Completed
Phase Phase 4
Start date April 2015
Completion date September 2015

See also
  Status Clinical Trial Phase
Terminated NCT01575379 - A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes Phase 4
Not yet recruiting NCT04084886 - TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
Recruiting NCT04570735 - MRI Biomarkers in Diabetic Kidney Disease
Completed NCT03165240 - This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated Phase 1
Completed NCT01968668 - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) Phase 2
Completed NCT02552277 - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy Phase 2
Recruiting NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Terminated NCT02410005 - Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL) Phase 2/Phase 3
Unknown status NCT01918488 - Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT03165227 - This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) Phase 1
Not yet recruiting NCT04929379 - A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes Phase 2
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Completed NCT03618420 - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Phase 1/Phase 2
Active, not recruiting NCT03334318 - PERL Continuous Glucose Monitoring (CGM) Study
Not yet recruiting NCT03284996 - Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus. N/A
Completed NCT04380584 - Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
Recruiting NCT01320345 - The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. Phase 3
Not yet recruiting NCT03288571 - Use of Wharton Jelly in Diabetic Nephropathy Phase 1/Phase 2